Trial Profile
A Phase II, Multicenter, Open Label Study to Evaluate the Pharmacodynamics of Nivolumab in Combination with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Brain cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Biomarker; Pharmacodynamics
- Acronyms IPINIVO
- Sponsors Agenus
- 12 Apr 2018 Status changed from active, no longer recruiting to completed.
- 02 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Aug 2017 Status changed from not yet recruiting to recruiting.